Stellar Biotechnologies Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market

PORT HUENEME, CA OTCQB, SBOTF, (Marketwired Aug 28, 2015) Stellar Biotechnologies, Inc. ( Stellar or the Company ) (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ( KLH ), today announced that, subject to regulatory approval, the Company will proceed with a consolidation of its issued and outstanding common shares (the Shares ) on the basis of one (1) post-consolidated common Share for every ten (10) pre-consolidated Shares (the Reverse Split ). The Company s Board of Directors approved the Reverse Split on August 26, 2015, in preparation for its planned uplisting to the NASDAQ Capital Market ( NASDAQ ). The Company has filed an application to have its common stock approved for trading on NASDAQ and the Reverse Split is intended to fulfill one of the quantitative requirements for listing. However, there can be no assurance that NASDAQ will approve the Company s application or, if the Company s stock is uplisted, that the Company wi


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: